Theralase Technologies Inc. (TSXV:TLT)
Canada · Delayed Price · Currency is CAD | Market Cap | 55.89M +14.4% |
| Revenue (ttm) | 802.46K -24.9% |
| Net Income | -3.79M |
| EPS | -0.01 |
| Shares Out | 310.48M |
| PE Ratio | n/a |
| Forward PE | 36.00 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 306,004 |
| Open | 0.1850 |
| Previous Close | 0.1850 |
| Day's Range | 0.1800 - 0.1850 |
| 52-Week Range | 0.1450 - 0.4100 |
| Beta | 0.49 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 27, 2026 |
About Theralase Technologies
Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research, development, and commercialization of energy activated small molecules and associated drug formulations in Canada, the United States, and internationally. The company operates in two segments, Drug Division and Device Division. It engages in the research and development of Rutherrin, an injectable form of Ruvidar for the treatment of glio blastoma multiforme, a form of brain cancer, non-small cell lung cancer, pancreatic cancer, colorectal cancer, and... [Read more]
Financial Performance
In 2025, Theralase Technologies's revenue was 816,468, a decrease of -20.99% compared to the previous year's 1.03 million. Losses were -4.12 million, -3.18% less than in 2024.
Financial StatementsNews
Theralase(R) Releases Q2 2026 Financial Statements
Theralase(R) Provides Updates on its Phase II Bladder Cancer Clinical Study and Oncology Pipeline Toronto, Ontario--(Newsfile Corp. - August 28, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB...
Theralase Technologies Earnings release: Q2 2026
Theralase Technologies released its Q2 2026 earnings on August 28, 2026, summarizing the period's financial results.
Theralase Technologies Registration statement: Q2 2026
Theralase Technologies filed a registration statement on August 28, 2026, providing details about a securities offering with the SEC.
Theralase Technologies Registration statement: Q2 2026
Theralase Technologies filed a registration statement on August 28, 2026, providing details about a securities offering with the SEC.
Theralase(R) Closes C$3.6 Million Brokered Financing
Toronto, Ontario--(Newsfile Corp. - August 24, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the...
Theralase(R) Announces $5 Million Brokered LIFE Offering
Toronto, Ontario--(Newsfile Corp. - August 10, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the...
Theralase(R) Grants Stock Options
Toronto, Ontario--(Newsfile Corp. - August 7, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the ...
Theralase(R) Engages Global One Media to Expand Global Investor Awareness
Toronto, Ontario--(Newsfile Corp. - August 4, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the ...
Theralase(R) Receives Receipt for C$100 Million Base Shelf Prospectus
Toronto, Ontario--(Newsfile Corp. - June 30, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the r...
Theralase Technologies Earnings Call Transcript: Q1 2026
Q1 2026 saw a 45% revenue increase and a 30% reduction in net loss, driven by device sales and cost controls. Clinical milestones include completed enrollment in the phase II bladder cancer study and plans for a new drug application in Q3 2026, with regulatory decisions expected in H1 2027.
Theralase Technologies Registration statement: Q1 2026
Theralase Technologies filed a registration statement on June 9, 2026, providing details about a securities offering with the SEC.
Theralase Technologies Registration statement: Q1 2026
Theralase Technologies filed a registration statement on June 9, 2026, providing details about a securities offering with the SEC.
Theralase Technologies Earnings release: Q1 2026
Theralase Technologies released its Q1 2026 earnings on June 9, 2026, summarizing the period's financial results.
Theralase(R) Releases Q1 2026 Financial Statements
Theralase(R) Provides an Update on its Phase II Bladder Cancer Clinical Study Toronto, Ontario--(Newsfile Corp. - May 29, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" ...
Theralase(R) Closes C$4.8 Million Offering
Toronto, Ontario--(Newsfile Corp. - May 20, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the re...
Theralase Technologies Earnings Call Transcript: Q4 2025
Completed phase II bladder cancer study enrollment, reported strong interim efficacy and safety, and maintained disciplined financial management amid declining device revenues. Preparing for regulatory submissions in 2026 and expanding pipeline into multiple oncology and virology indications.
Theralase Technologies Registration statement: Q4 2025
Theralase Technologies filed a registration statement on May 12, 2026, providing details about a securities offering with the SEC.
Theralase Technologies Registration statement: Q4 2025
Theralase Technologies filed a registration statement on May 12, 2026, providing details about a securities offering with the SEC.
Theralase Technologies Earnings release: Q4 2025
Theralase Technologies released its Q4 2025 earnings on May 12, 2026, summarizing the period's financial results.
Theralase(R) Announces $4 Million Brokered LIFE Offering
THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Toronto, Ontario--(Newsfile Corp. - May 5, 2026) - Theralase® Technologies Inc. (TSXV: TLT...
Theralase(R) Releases 2025 Annual Financial Statements and Provides Clinical Study Update
Toronto, Ontario--(Newsfile Corp. - May 4, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the res...
Theralase(R) Reports Complete Response with X-Ray-Activated Rutherrin(R) in Muscle Invasive Bladder Cancer Preclinical Study
Toronto, Ontario--(Newsfile Corp. - April 13, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the ...
Theralase(R) Closes $CAN 2.66 Million Financing
Toronto, Ontario--(Newsfile Corp. - April 10, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the ...
Theralase(R) Closes $1.1 M Non-Brokered Private Placement
Toronto, Ontario--(Newsfile Corp. - March 10, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the ...
Theralase(R) Demonstrates That X-Ray-Activated Rutherrin(R) Is Significantly More Effective than Radiation Alone in the Destruction of Muscle Invasive Bladder Cancer
Toronto, Ontario--(Newsfile Corp. - March 9, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the r...